PD-1信号促进小鼠肿瘤浸润髓源性抑制细胞及胃肿瘤发生
该研究在小鼠胃癌模型中探究PD-1抑制剂耐药机制及PD-L1的作用。发现抗PD-1早期给药可减小肿瘤并增加T细胞浸润,但对已形成肿瘤无效;MDSC存在时PD-1阻断无效。5-氟尿嘧啶联合奥沙利铂可减少MDSC、增强抗PD-1疗效,但诱导肿瘤PD-L1表达。胃上皮细胞表达PD-L1促进MNU和H felis诱导的肿瘤发生及MDSC积聚。
要点
- 抗PD-1早期给药可减小胃肿瘤并增加T细胞浸润,但对已形成肿瘤无效。
- MDSC存在时抗PD-1无效,化疗减少MDSC可增强抗PD-1疗效但诱导PD-L1。
- 胃上皮PD-L1表达促进MNU和H felis诱导的肿瘤发生及MDSC积聚。
核心结论
- 在小鼠胃癌模型中,5-氟尿嘧啶和奥沙利铂减少MDSC数量以增强抗PD-1效果,促进CD8+ T细胞肿瘤浸润。
- 但这些化疗药物也诱导肿瘤细胞表达PD-L1,胃上皮细胞PD-L1表达促进MNU和H felis诱导的肿瘤发生及MDSC积聚。
- PD-L1表达的时间和部位在胃肿瘤发生中很重要,设计治疗方案时应考虑。
研究设计与样本
- 研究使用胃泌素缺陷小鼠给予N-甲基-N-亚硝基脲(MNU)饮水及H felis诱导胃肿瘤。
- 还使用H/K-ATPase-hIL1B小鼠,其自发在胃窦-胃体交界处发生胃肿瘤,壁细胞组成性分泌白介素1B。
- 小鼠在肿瘤形成前注射抗PD-1抗体或同型对照,或在肿瘤形成后注射抗PD-1联合5-氟尿嘧啶和奥沙利铂,或抗Gr-1抗体耗竭MDSC。
- 生成在胃上皮或髓系特异性表达PD-L1的敲入小鼠。
主要发现
- 在胃泌素缺陷小鼠肿瘤生长前给予抗PD-1显著减小肿瘤大小并增加T细胞肿瘤浸润。
- 抗PD-1单药对已形成的肿瘤无显著影响。
- 在H/K-ATPase-hIL-1β小鼠MDSC存在时,早期或晚期给予抗PD-1均未减少肿瘤生长。
- 5-氟尿嘧啶和奥沙利铂联合减少MDSC、增加瘤内CD8+ T细胞数量并增加肿瘤对抗PD-1的应答,但导致肿瘤PD-L1表达增加。
- 肿瘤或免疫细胞表达PD-L1增加MNU诱导的小鼠胃肿瘤发生。
临床怎么用
- 在胃癌治疗中,抗PD-1的时机可能影响疗效,早期使用可能更有效。
- 化疗减少MDSC可增强抗PD-1疗效,但需注意化疗诱导的PD-L1表达可能影响后续治疗。
- PD-L1表达的部位和时间应纳入治疗方案设计的考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Immune checkpoint inhibitors have limited efficacy in many tumors. We investigated mechanisms of tumor resistance to inhibitors of programmed cell death-1 (PDCD1, also called PD-1) in mice with gastric cancer, and the role of its ligand, PD-L1. METHODS: Gastrin-deficient mice were given N-methyl-N-nitrosourea (MNU) in drinking water along with Helicobacter felis to induce gastric tumor formation; we also performed studies with H/K-ATPase-hIL1B mice, which develop spontaneous gastric tumors at the antral-corpus junction and have parietal cells that constitutively secrete interleukin 1B. Mice were given injections of an antibody against PD-1 or an isotype control before tumors developed, or anti-PD-1 and 5-fluorouracil and oxaliplatin, or an antibody against lymphocyte antigen 6 complex locus G (also called Gr-1), which depletes myeloid-derived suppressor cells [MDSCs]), after tumors developed. We generated knock-in mice that express PD-L1 specifically in the gastric epithelium or myeloid lineage. RESULTS: When given to gastrin-deficient mice before tumors grew, anti-PD-1 significantly reduced tumor size and increased tumor infiltration by T cells. However, anti-PD-1 alone did not have significant effects on established tumors in these mice. Neither early nor late anti-PD-1 administration reduced tumor growth in the presence of MDSCs in H/K-ATPase-hIL-1β mice. The combination of 5-fluorouracil and oxaliplatin reduced MDSCs, increased numbers of intra-tumor CD8+ T cells, and increased the response of tumors to anti-PD-1; however, this resulted in increased tumor expression of PD-L1. Expression of PD-L1 by tumor or immune cells increased gastric tumorigenesis in mice given MNU. Mice with gastric epithelial cells that expressed PD-L1 did not develop spontaneous tumors, but they developed more and larger tumors after administration of MNU and H felis, with accumulation of MDSCs. CONCLUSIONS: In mouse models of gastric cancer, 5-fluorouracil and oxaliplatin reduce numbers of MDSCs to increase the effects of anti-PD-1, which promotes tumor infiltration by CD8+ T cells. However, these chemotherapeutic agents also induce expression of PD-L1 by tumor cells. Expression of PD-L1 by gastric epithelial cells increases tumorigenesis in response to MNU and H felis, and accumulation of MDSCs, which promote tumor progression. The timing and site of PD-L1 expression is therefore important in gastric tumorigenesis and should be considered in design of therapeutic regimens.
引用
- Kim W, Chu TH, Nienhüser H, et al. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology. 2020. PMID: 33129844. doi:10.1053/j.gastro.2020.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。